Literature DB >> 23321149

Contralateral psoas seroma after transpsoas lumbar interbody fusion with bone morphogenetic protein-2 implantation.

Fadi Taher1, Darren R Lebl, Alexander P Hughes, Federico P Girardi.   

Abstract

BACKGROUND CONTEXT: The lateral transpsoas approach to interbody fusion of the lumbar spine (lateral lumbar interbody fusion [LLIF]) with recombinant human bone morphogenetic protein-2 (BMP-2) augmentation has been increasingly performed in recent years. Potential side effects and adverse sequelae of BMP-2 in the acute setting remain to be fully elucidated.
PURPOSE: To review the literature for reports of complications related to BMP-2 implantation in lumbar spinal surgery and present a case of a contralateral psoas muscle seroma after LLIF with BMP-2 implantation. STUDY
DESIGN: Case report and literature review.
METHODS: The PubMed database was searched for articles related to adverse events to BMP-2 in lumbar spinal surgery. We report the case of a 57-year-old woman who underwent routine right-sided transpsoas approach for LLIF with the use of BMP-2 at our institution and developed a left-sided psoas muscle fluid accumulation 2 weeks postoperatively.
RESULTS: No reports of complications contralateral to an LLIF approach attributable to an inflammatory response to BMP-2 were identified in the English literature. In the presented patient, a large (4.2×6.5×2.7 cm) left-sided sterile intramuscular psoas fluid collection was seen on a magnetic resonance imaging study obtained on postoperative day 14. At a 6-month follow-up, left-sided L5 radiculopathy resulting in 4/5 foot drop was confirmed by electromyography. The patient reported here represents the only case of a contralateral psoas seroma with suspected association to BMP-2 utilization in LLIF encountered at our institution.
CONCLUSIONS: A serous psoas muscle fluid accumulation after BMP-2 implantation may rarely occur contralateral to the surgical approach for LLIF. Further characterization of complications related to BMP-2 implantation after lumbar spinal surgery will help guide preoperative informed decision making and the management of this unusual postoperative adverse event.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23321149     DOI: 10.1016/j.spinee.2012.11.052

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  9 in total

Review 1.  MIS lateral spine surgery: a systematic literature review of complications, outcomes, and economics.

Authors:  Jeff A Lehmen; Edward J Gerber
Journal:  Eur Spine J       Date:  2015-04-08       Impact factor: 3.134

Review 2.  Lateral Lumbar Interbody Fusion-Outcomes and Complications.

Authors:  Stephan N Salzmann; Jennifer Shue; Alexander P Hughes
Journal:  Curr Rev Musculoskelet Med       Date:  2017-12

3.  Effectiveness and safety of transforaminal lumbar interbody fusion in patients with previous laminectomy.

Authors:  Hossein Elgafy; Doug Olson; Jiayong Liu; Caitlin Lewis; Hassan Semaan
Journal:  Eur Spine J       Date:  2014-12-20       Impact factor: 3.134

Review 4.  A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2.

Authors:  Aaron W James; Gregory LaChaud; Jia Shen; Greg Asatrian; Vi Nguyen; Xinli Zhang; Kang Ting; Chia Soo
Journal:  Tissue Eng Part B Rev       Date:  2016-04-19       Impact factor: 6.389

5.  Symptomatic contralateral osteophyte fracture with migration causing lumbar plexopathy during oblique lumbar interbody fusion: illustrative case.

Authors:  Brenton Pennicooke; Jeremy Guinn; Dean Chou
Journal:  J Neurosurg Case Lessons       Date:  2021-07-05

6.  A consensus statement regarding the utilization of BMP in spine surgery.

Authors:  Brett Walker; John Koerner; Sriram Sankarayanaryanan; Kris Radcliff
Journal:  Curr Rev Musculoskelet Med       Date:  2014-09

7.  Mini-Open Access for Lateral Lumbar Interbody Fusion: Indications, Technique, and Outcomes.

Authors:  Stephan N Salzmann; Gary A Fantini; Ichiro Okano; Andrew A Sama; Alexander P Hughes; Federico P Girardi
Journal:  JBJS Essent Surg Tech       Date:  2019-11-01

8.  Opposing TNF-α/IL-1β- and BMP-2-activated MAPK signaling pathways converge on Runx2 to regulate BMP-2-induced osteoblastic differentiation.

Authors:  R-L Huang; Y Yuan; J Tu; G-M Zou; Q Li
Journal:  Cell Death Dis       Date:  2014-04-17       Impact factor: 8.469

9.  Identification of the effector domain of biglycan that facilitates BMP-2 osteogenic function.

Authors:  Prapaporn Jongwattanapisan; Masahiko Terajima; Patricia A Miguez; William Querido; Hideaki Nagaoka; Noriko Sumida; Elizabeth Grace Gurysh; Kristy M Ainslie; Nancy Pleshko; Lalith Perera; Mitsuo Yamauchi
Journal:  Sci Rep       Date:  2018-05-04       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.